Register for a live broadcast to learn more about TRODELVY (sacituzumab govitecan-hziy) with Dr. Hope S. Rugo

Finding the Fit for Immunotherapy in Prostate Cancer

MICHAEL LAI, ARNP | August 27, 2019

Prostate cancer tumors tend to be "cold," meaning that they may have difficulty responding to immunotherapy treatment. But combining agents may help improve their responsiveness, explained Michael Lai, ARNP, a nurse practitioner at Seattle Cancer Care Alliance. 


So in prostate cancer, we're looking at, for example, immunotherapy and utilizing this in that context. For immunotherapy, what we're doing right now is, as opposed to doing a single-agent model, using dual agents, because prostate cancer can tend to be a relatively "cold" tumor. So if you use something like docetaxel first or in conjunction with immunotherapies like pembrolizumab (Keytruda) or standard-of-care agents such as abiraterone (Zytiga), the idea is: can we warm up the tumor so that the prostate cancer is more susceptible to immunotherapy agents such as pembrolizumab or others.

External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.